

Olivier Tredan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/422150/publications.pdf>

Version: 2024-02-01

120
papers

8,506
citations

81900

39
h-index

46799

89
g-index

140
all docs

140
docs citations

140
times ranked

15351
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug Resistance and the Solid Tumor Microenvironment. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1441-1454.	6.3	1,795
2	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3638-3646.	1.6	1,099
3	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1324-1334.	10.7	897
4	Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas. <i>Cancer Research</i> , 2009, 69, 5383-5391.	0.9	610
5	A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). <i>Annals of Oncology</i> , 2016, 27, 812-818.	1.2	234
6	Class III β -tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 2001-2007.	4.1	224
7	Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 5423-5434.	0.9	200
8	Expression of Class III β -Tubulin Is Predictive of Patient Outcome in Patients with Non-Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 5481-5486.	7.0	193
9	The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. <i>Lancet Oncology</i> , The, 2011, 12, 693-702.	10.7	147
10	A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. <i>Cancer Letters</i> , 2014, 343, 33-41.	7.2	133
11	A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. <i>Nature Communications</i> , 2016, 7, 12222.	12.8	113
12	Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. <i>Oncotarget</i> , 2012, 1, 432-440.	4.6	102
13	High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. <i>European Journal of Cancer</i> , 2020, 135, 251-259.	2.8	102
14	Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. <i>Annals of Oncology</i> , 2013, 24, 2808-2813.	1.2	97
15	Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. <i>Annals of Oncology</i> , 2014, 25, 1570-1577.	1.2	90
16	IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. <i>Science Immunology</i> , 2020, 5, .	11.9	86
17	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. <i>Breast Cancer Research</i> , 2013, 15, R105.	5.0	80
18	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. <i>Journal of Clinical Oncology</i> , 2020, 38, 2762-2772.	1.6	80

#	ARTICLE	IF	CITATIONS
19	Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. <i>Annals of Oncology</i> , 2007, 18, 256-262.	1.2	76
20	Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. <i>European Journal of Cancer</i> , 2018, 95, 75-84.	2.8	72
21	Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial. <i>British Journal of Cancer</i> , 2014, 111, 17-24.	6.4	70
22	Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO). <i>Journal of Clinical Oncology</i> , 2020, 38, 734-743.	1.6	69
23	Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. <i>Annals of Oncology</i> , 2015, 26, 325-332.	1.2	67
24	Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay. <i>Oncolimmunology</i> , 2016, 5, e1100791.	4.6	66
25	Body weight change in women receiving adjuvant chemotherapy for breast cancer: A French prospective study. <i>Clinical Nutrition</i> , 2010, 29, 187-191.	5.0	65
26	Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 127-138.	2.3	63
27	ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. <i>Annals of Oncology</i> , 2015, 26, 1353-1362.	1.2	63
28	cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 49, 363-370.	2.0	62
29	Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial. <i>Annals of Oncology</i> , 2017, 28, 590-596.	1.2	58
30	Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. <i>Targeted Oncology</i> , 2012, 7, 253-265.	3.6	57
31	A Systematic Evaluation of Blood Serum and Plasma Pre-Analytcs for Metabolomics Cohort Studies. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2035.	4.1	56
32	Activation of rapid oestrogen signalling in aggressive human breast cancers. <i>EMBO Molecular Medicine</i> , 2012, 4, 1200-1213.	6.9	55
33	Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints. <i>Cancer Research</i> , 2018, 78, 3604-3618.	0.9	53
34	UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). <i>ESMO Open</i> , 2019, 4, e000562.	4.5	53
35	Role of JMJD6 in Breast Tumourigenesis. <i>PLoS ONE</i> , 2015, 10, e0126181.	2.5	48
36	The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone. <i>Cancer Research</i> , 2009, 69, 940-947.	0.9	47

#	ARTICLE	IF	CITATIONS
37	Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 8-15.	2.4	47
38	Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. <i>Targeted Oncology</i> , 2013, 8, 243-251.	3.6	44
39	Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. <i>European Journal of Cancer</i> , 2013, 49, 1673-1682.	2.8	42
40	Frequency of depression among oncology outpatients and association with other symptoms. <i>Supportive Care in Cancer</i> , 2012, 20, 2795-2802.	2.2	41
41	Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 326-333.	7.0	40
42	LKB1 regulates PRMT5 activity in breast cancer. <i>International Journal of Cancer</i> , 2019, 144, 595-606.	5.1	34
43	Validation of prognostic scores for survival in cancer patients beyond first-line therapy. <i>BMC Cancer</i> , 2011, 11, 95.	2.6	33
44	Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. <i>Targeted Oncology</i> , 2015, 10, 189-198.	3.6	33
45	Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. <i>BMC Cancer</i> , 2011, 11, 213.	2.6	31
46	CD4 lymphopenia to identify end-of-life metastatic cancer patients. <i>European Journal of Cancer</i> , 2013, 49, 1080-1089.	2.8	31
47	Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. <i>Oncogene</i> , 2012, 31, 3516-3524.	5.9	30
48	The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer. <i>Oncogene</i> , 2019, 38, 4015-4027.	5.9	28
49	Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e12306.	3.7	27
50	Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. <i>Annals of Oncology</i> , 2010, 21, 759-765.	1.2	25
51	Deterioration of Physical Activity Level and Metabolic Risk Factors After Early-Stage Breast Cancer Diagnosis. <i>Cancer Nursing</i> , 2015, 38, E1-E9.	1.5	25
52	A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study. <i>Annals of Oncology</i> , 2016, 27, 1020-1029.	1.2	25
53	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 601-609.	2.5	25
54	Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study. <i>Clinical Cancer Research</i> , 2021, 27, 5482-5491.	7.0	25

#	ARTICLE	IF	CITATIONS
55	Non-genomic signaling of steroid receptors in cancer. <i>Molecular and Cellular Endocrinology</i> , 2021, 538, 111453.	3.2	24
56	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 3190-3204.	1.6	23
57	Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. <i>Bulletin Du Cancer</i> , 2010, 97, E23-E32.	1.6	21
58	A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1148-1157.	6.4	20
59	Feasibility of an exercise and nutritional intervention for weight management during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial. <i>Supportive Care in Cancer</i> , 2019, 27, 3449-3461.	2.2	20
60	Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival. <i>British Journal of Cancer</i> , 2017, 116, 356-361.	6.4	19
61	Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients. <i>Oncotarget</i> , 2017, 8, 83570-83584.	1.8	18
62	A Personalized Physical Activity Program With Activity Trackers and a Mobile Phone App for Patients With Metastatic Breast Cancer: Protocol for a Single-Arm Feasibility Trial. <i>JMIR Research Protocols</i> , 2018, 7, e10487.	1.0	18
63	Percutaneous cryoablation of breast tumours in patients with stable metastatic breast cancer: safety, feasibility and efficacy. <i>British Journal of Radiology</i> , 2018, 91, 20170500.	2.2	17
64	Physical activity preferences before and after participation in a 6-month physical activity intervention among women with metastatic breast cancer. <i>European Journal of Cancer Care</i> , 2020, 29, e13169.	1.5	16
65	Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 601-613.	2.5	16
66	BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 775-783.	2.5	15
67	Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. <i>Medical Oncology</i> , 2014, 31, 76.	2.5	13
68	Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2773.	4.1	13
69	Concomitant resistance and early-breast cancer: should we change treatment strategies?. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 271-283.	5.9	11
70	Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1238-1247.	4.1	11
71	Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme. <i>European Journal of Cancer</i> , 2019, 118, 156-165.	2.8	11
72	Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 187-195. ^{2,5}		10

#	ARTICLE	IF	CITATIONS
73	Depression assessment by oncologists and palliative care physicians. <i>Palliative and Supportive Care</i> , 2012, 10, 255-263.	1.0	10
74	Design of a randomised controlled trial of adapted physical activity during adjuvant treatment for localised breast cancer: the PASAPAS feasibility study. <i>BMJ Open</i> , 2013, 3, e003855.	1.9	10
75	Impact of Physical Activity on Oxidative Stress Markers in Patients with Metastatic Breast Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-9.	4.0	9
76	The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. <i>Oncotarget</i> , 2015, 6, 26388-26399.	1.8	9
77	A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design. <i>Trials</i> , 2022, 23, 193.	1.6	9
78	Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study. <i>Oncology Letters</i> , 2016, 11, 1859-1865.	1.8	8
79	Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfilER 01 trial. <i>Translational Oncology</i> , 2020, 13, 100870.	3.7	8
80	Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer. <i>Scientific Reports</i> , 2020, 10, 10757.	3.3	8
81	Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer. <i>BMC Research Notes</i> , 2010, 3, 164.	1.4	7
82	Trends in cancer-targeted antibody-drug conjugates. <i>Targeted Oncology</i> , 2014, 9, 1-8.	3.6	7
83	Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant. <i>Breast Cancer Research</i> , 2021, 23, 57.	5.0	7
84	Abstract PD5-1: Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer. <i>Cancer Research</i> , 2015, 75, PD5-1-PD5-1.	0.9	7
85	Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study. <i>Bulletin Du Cancer</i> , 2011, 98, E80-E89.	1.6	6
86	Survivorship in untreated breast cancer patients. <i>Medical Oncology</i> , 2015, 32, 466.	2.5	6
87	Effects of an Exercise and Nutritional Intervention on Circulating Biomarkers and Metabolomic Profiling During Adjuvant Treatment for Localized Breast Cancer: Results From the PASAPAS Feasibility Randomized Controlled Trial. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542097766.	2.0	6
88	Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13512.	4.1	6
89	Primary Ovarian Borderline Tumor in the Inguinal Lymph Node. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 167-170.	1.4	5
90	Design and methods of a national, multicenter, randomized and controlled trial to assess the efficacy of a physical activity program to improve health-related quality of life and reduce fatigue in women with metastatic breast cancer: ABLE02 trial. <i>BMC Cancer</i> , 2020, 20, 622.	2.6	5

#	ARTICLE	IF	CITATIONS
91	Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing. <i>Cancer Research</i> , 2020, 80, 2190-2203.	0.9	4
92	Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR). <i>Gynecologic Oncology</i> , 2022, 164, 18-26.	1.4	4
93	Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study. <i>The Lancet Healthy Longevity</i> , 2022, 3, e176-e185.	4.6	4
94	First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer. <i>Bulletin Du Cancer</i> , 2012, 99, E18-E25.	1.6	3
95	Targeted treatments for breast cancer: a step forward. <i>Lancet Oncology</i> , The, 2013, 14, 438-439.	10.7	3
96	Tumor Molecular Profiling: Pediatric Results of the ProfilER Study. <i>JCO Precision Oncology</i> , 2020, 4, 785-795.	3.0	3
97	Abstract P5-19-17: Final results of the phase I "HIT" study: A multicenter phase II study evaluating trastuzumab administered by intrathecal injection for leptomeningeal meningitis of HER2+ metastatic breast cancer (MBC). , 2015, , .		3
98	Arobase: A phase III trial of exemestane (Exe) and bevacizumab (BEV) as maintenance therapy in patients (pts) with metastatic breast cancer (MBC) treated in first line with paclitaxel (P) and BEV. <i>A Gineco study.. Journal of Clinical Oncology</i> , 2014, 32, 501-501.	1.6	3
99	Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfilER trial. <i>Medical Oncology</i> , 2022, 39, 4.	2.5	3
100	Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfilER program. <i>Translational Oncology</i> , 2022, 15, 101266.	3.7	3
101	Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. <i>Breast</i> , 2021, 57, 43-48.	2.2	2
102	Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5556-5556.	1.6	2
103	Genomic alterations to predict response to irinotecan-based chemotherapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 586-586.	1.6	2
104	Prevalence of depressive syndrome in patients with breast cancer treated with or without aromatase inhibitors. <i>Oncologie</i> , 2015, 17, 587-594.	0.7	1
105	Therogenetics: transferring GWAS technology to the clinic. <i>Mutagenesis</i> , 2015, 30, 213-215.	2.6	1
106	PI3K targeting in breast cancer: the end of the beginning?. <i>Lancet Oncology</i> , The, 2016, 17, 696-697.	10.7	1
107	Identifying actionable targets in advanced cancer patients: Preliminary results from the Profiler program.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2621-2621.	1.6	1
108	SHIVA: Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer. <i>PFS ratio from patients who crossed-over.. Journal of Clinical Oncology</i> , 2016, 34, 2535-2535.	1.6	1

#	ARTICLE	IF	CITATIONS
109	ELYPSE-7: A randomized, placebo-controlled, phase 2a study evaluating the impact of IL-7 on CD4 count, hematological toxicity, and tumor progression in metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 3033-3033.	1.6	1
110	Management of Antiangiogenic Agents. , 2016, , 69-77.		1
111	La mÃ©tabolomique: un nouvel outil pour la recherche translationnelle en cancÃ©rologie. Oncologie, 2010, 12, 409-415.	0.7	0
112	Mechanisms of resistance to endocrine therapies for breast cancer. Hormone Molecular Biology and Clinical Investigation, 2012, 9, 165-171.	0.7	0
113	Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial. JCO Precision Oncology, 2018, 2, 1-11.	3.0	0
114	Abstract LB-165: Low TCR diversity (divpenia) is a new prognosis factor of overall survival in metastatic breast cancer. , 2011, , .		0
115	Abstract 2267: Long term prognostic impact of CD4 and CD8 lymphopenia and rapid recovery in a cohort of 220 patients with a 10 years follow-up. , 2011, , .		0
116	Abstract LB-171: Randomized phase II trial comparing therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Preliminary results of the feasibility of the SHIVA trial.. , 2013, , .		0
117	Efficacy and toxicity profile of eribulin mesylate for metastatic breast cancer (MBC) patients (pts) in the routine clinic: A French observational study.. Journal of Clinical Oncology, 2014, 32, e11555-e11555.	1.6	0
118	Abstract 2574: Interleukin-7 (CYT107) treatment in lymphopenic 1st line metastatic breast carcinoma patients treated with chemotherapy regimen (Capecitabine) favors the restoration of T-cell subsets number. , 2014, , .		0
119	Abstract CT333: Elypse-7: A randomized, placebo-controlled, Phase 2a evaluating the impact of IL-7 immunotherapy on CD4 count, risks of severe haematological toxicity and tumor progression in metastatic breast cancer patients. , 2014, , .		0
120	Abstract LB-253: A comprehensive evaluation of immune checkpoints ligands (ICPLs) in more than 1,000 cancer cell lines (CCLs) identifies specific expression patterns. , 2014, , .		0